![FIRST FDA-APPROVED TARGETED TREATMENT FOR METex14 in mNSCLC](https://usim.beprod.tabrecta-hcp.com/sites/tabrecta_hcp_com/files/styles/hero_full_width_width_2560/public/2023-10/tabrecta-mnsclc-hero-image-desktop_crop.png?itok=5p7INLq3)
MET, mesenchymal-epithelial transition; METex14, MET exon 14 skipping; mNSCLC, metastatic non-small cell lung cancer.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
*See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for detailed recommendations, including other options.